Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients

Gupta, Tanush; Kolte, Dhaval; Khera, Sahil; Goel, Kashish; Aronow, Wilbert S.; Cooper, Howard A.; Jain, Diwakar; Rihal, Charanjit S.; Fonarow, Gregg C.; Panza, Julio A.; Bhatt, Deepak L.

doi:10.1001/jamacardio.2016.5131

Cited by 21 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study cohort was further stratified by CKD status into the following groups: non-CKD; not dialysis-dependent CKD (ICD-9: 585.1–585.5, 585.9); and ESRD (ICD-9: 585.6 or with procedure code for hemodialysis or peritoneal dialysis: 39.95, 54.98, except when dialysis was performed for AKI: 584.5 to 584.9). This approach has been used to accurately identify patients in the NIS database with CKD or ESRD [13, 14].…”

Section: Methodsmentioning

confidence: 99%

Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample

Chen

Liu

et al. 2019

BMC Nephrol

View full text Add to dashboard Cite

Background Chronic kidney disease (CKD) and end stage renal disease (ESRD) are not well characterized in prostate cancer patients. This study aimed to examine the clinical characteristics and postsurgical outcomes of patients with or without CKD and ESRD undergoing radical prostatectomy for prostate cancer. Methods This population-based, retrospective study used patient data from the Nationwide Inpatient Sample, the largest all-payer US inpatient care database. From 2005 to 2014, 136,790 male patients aged > 20 years diagnosed with prostate cancer and who received radical prostatectomy were included. Postoperative complications, postoperative acute kidney injury (AKI) and urinary complications, and length of hospital stay were compared between patients with or without underlying CKD and ESRD. Results After adjusting for relevant factors, the CKD group had a significantly higher risk of postoperative complications than the non-CKD group. In addition, the CKD group had a 5-times greater risk of postoperative AKI and urinary complications than the non-CKD group. Both CKD and ESRD groups had significantly longer hospital stays than the non-CKD group. Patients receiving RARP had a lower risk of postoperative complications than those who received open radical prostatectomy, regardless of having CKD or not. Both non-CKD and CKD patients receiving RARP had shorter hospital stays than those who received open surgery. Conclusions Prostate cancer patients with underlying CKD had significantly greater risk of postoperative complications, postoperative AKI and urinary complications, and longer hospital stays than those without CKD. The use of RARP significantly shortened hospital stays and reduced complications for these patients. Electronic supplementary material The online version of this article (10.1186/s12882-019-1455-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Methodsmentioning

confidence: 99%

Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample

Chen

Liu

et al. 2019

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Values were missing for <5% of individuals for most variables; however, type of medical insurance and serum globulin were missing for 10.53% and 14.78% of patients (Table S1 in the Online Supplementary Document ), respectively. Missing data were imputed with medians or dominant category depending on whether they were continuous or categorical information [ 16 , 17 ].…”

Section: Methodsmentioning

confidence: 99%

Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19

Wu¹,

Jin²,

Peng³

et al. 2022

J Glob Health

View full text Add to dashboard Cite

Background The adverse effects of proton pump inhibitors (PPIs) on pneumonia have been well reported. However, the relationship between the use of PPIs and the adverse outcomes of coronavirus disease 2019 (COVID-19) is currently inconclusive. In this study, we aimed to explore the relationship between the use of PPIs and the in-hospital mortality among patients who were laboratory-confirmed SARS-CoV-2. Methods Data was derived from 2 hospitals which both were the first batch of SARS-CoV-2 specialist hospitals with four types of sensitivity analyses. This cohort included 4634 patients older than 18 years who were laboratory-confirmed SARS-CoV-2. Endpoints were death in hospital (primary) and the recovery of COVID-19 (secondary: the time of COVID-19 nucleic acid testing turning negative). Results In the entire cohort, there were 3588 non-users, 399 ≤ 0.5 defined daily dose (DDD) PPIs users, 483 1 DDD users, and 164 ≥ 1.5 DDD users. The multivariate logistic regression analysis (odds ratio (OR) = 3.63, 95% confidence interval (CI) = 1.83-7.23, P = 0.0002) and four types of sensitivity analyses showed higher mortality in patients using PPIs during hospitalization, while the relationship between different PPIs dosages and the hospital mortality remained insignificant. Usage of the PPIs significantly prolongs the time of COVID-19 nucleic acid testing turning negative. Conclusions The use of PPIs may increase the risk of in-hospital death of patients who were laboratory-confirmed SARS-CoV-2, which means that physicians may need to re-evaluate the benefit-risk assessment of the use of PPIs during the COVID-19 pandemic.

show abstract

“…Despite favorable recent temporal trends in guideline-directed medical therapies [7] and invasive diagnostic and interventional approaches [8] in patients with established CV disease and CKD, these patients continue to face sub-optimal CV outcomes. Since fatal MIs appear to account for only ∼6% of cause-specific mortality in the CKD population based on the US Renal Data System 2015 Annual Data Report [1], a more global CV risk reduction approach may be favored over focus on diagnosis and prevention of MI in isolation.…”

Section: Optimizing Cardiovascular Care Of Patients With Ckdmentioning

confidence: 99%

Cardiac Troponins in Chronic Kidney Disease: A Marker of Global Cardiovascular Risk

Vaduganathan

Bhatt²

2017

Am J Nephrol

Self Cite

View full text Add to dashboard Cite

Management and Outcomes of ST-Segment Elevation Myocardial Infarction in US Renal Transplant Recipients

Abstract: In-hospital mortality rates in renal transplant recipients with STEMI are more favorable compared with those of patients with stage 5D CKD and approach those of the general population with STEMI.

Cited by 21 publications

References 29 publications

Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample

Post-surgical outcomes of patients with chronic kidney disease and end stage renal disease undergoing radical prostatectomy: 10-year results from the US National Inpatient Sample

Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with COVID-19

Cardiac Troponins in Chronic Kidney Disease: A Marker of Global Cardiovascular Risk

Contact Info

Product

Resources

About